Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21484876 | 0.83 | ABL1 (0.59) | MAPTALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL4408658 | 0.80 | PI4KB (0.57) | MAPTALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL16434538 | 0.80 | HDAC1 (0.60) | MAPTALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL4420194 | 0.80 | HDAC1 (0.65) | MAPTALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL838537 | 0.77 | SMN1; SMN2 (0.61) | MAPTALDH1A1SMN1; SMN2PI4KBNPC1 | |
| SCHEMBL2452315 | 0.77 | ELOVL1 (0.72) | MAPTALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4408570 | 0.76 | GAA (0.61) | MAPTALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4416778 | 0.76 | RAB9A (0.63) | MAPTMEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL480758 | 0.75 | MAPT (0.71) | MAPTALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL21586296 | 0.75 | KMT2A (0.74) | MAPTALDH1A1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12247029-B2 | Heterocyclic compounds as class II phosphoinositide 3-kinase inhibitors | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2025-03-11 | — | — | US | disclosed |
| EP-3802530-B1 | HETEROCYCLIC COMPOUNDS AS CLASS II PHOSPHOINOSITIDE 3-KINASE INHIBITORS | FORSCHUNGSVERBUND BERLIN EV (DE) | 2024-05-29 | — | — | EP | disclosed |
| US-20220332717-A1 | HETEROCYCLIC COMPOUNDS AS CLASS II PHOSPHOINOSITIDE 3-KINASE INHIBITORS | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2022-10-20 | — | — | US | disclosed |
| WO-2019234237-A1 | HETEROCYCLIC COMPOUNDS AS CLASS II PHOSPHOINOSITIDE 3-KINASE INHIBITORS | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2019-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12247029-B2 | Heterocyclic compounds as class II phosphoinositide 3-kinase inhibitors | PIK3CA, PIK3CD, PIK3C2B | MAPT 4587/4885ALDH1A1 4380/4885MEN1 1529/4885 |
| US-20220332717-A1 | HETEROCYCLIC COMPOUNDS AS CLASS II PHOSPHOINOSITIDE 3-KINASE INHIBITORS | PIK3CA, PIK3CD, PIK3C2B | MAPT 4587/4885ALDH1A1 4380/4885MEN1 1529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.